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Introduction {#sec1}
============

Human pluripotent stem cells (PSCs) are a promising source of transplantable neural progenitors for cell-replacement therapies to treat neurological conditions. One of the most anticipated applications is in Parkinson\'s disease (PD), where proof of principle for efficacy has already been established in clinical trials using fetal midbrain grafts ([@bib23], [@bib34]). Although these trials have been problematic due to variability in clinical outcome, more than 30 years of basic and clinical research has led to refinement of the approach, and identification of important criteria for establishment of stem cells as an alternative and potentially superior donor source ([@bib2], [@bib51]), for example the requirement that the implanted dopamine (DA) neurons establish a functional terminal network with appropriate targets in the host brain.

Detailed characterizations of fetal graft composition and structural integration have been fundamentally important for understanding graft-host connectivity and the relationship to functional outcome. Early xenografting studies using species-specific antibodies to identify fiber outgrowth from human or porcine fetal midbrain grafts placed homotopically into rat midbrain provided some of the first evidence that grafted neurons retained an intrinsic capacity for target-directed outgrowth, even in the adult host ([@bib26], [@bib56]). The development of transgenic reporter mice lead to more precise characterization of fiber outgrowth, including the first demonstrations of connectivity on a neuronal-subtype-specific basis (for review see [@bib50]). Grafting of fetal midbrain from TH-GFP ([@bib43]) or *Pitx3*-EGFP ([@bib58]) mice allowed for precise identification of graft-derived (GFP^+^) DA fiber patterns, even in the presence of residual host DA fibers, and showed that implanted DA neurons not only innervated the host striatum but also innervated appropriate extra-striatal targets, including the cortex, amygdala, and septum ([@bib49]). These studies also showed that the major A9 and A10 DA neuronal subclasses maintained developmentally appropriate target preference, innervating striatum and frontal cortex, respectively, and importantly that A9-specific innervation of dorsolateral striatum was required for restoration of motor function ([@bib21]).

The first histological characterizations of neural grafts generated from human stem cells were limited to identification of the graft core using antibodies specific for a human nuclear antigen ([@bib5], [@bib11], [@bib38], [@bib45], [@bib57]). Recently however, more sophisticated approaches using human stem cell lines ubiquitously expressing fluorescent reporters ([@bib14], [@bib15], [@bib17], [@bib35], [@bib37], [@bib40], [@bib47]) and human-specific antibodies against cell-surface proteins, such as polysialated nuclear cell adhesion molecule (NCAM) ([@bib22], [@bib30], [@bib31], [@bib48]), have dramatically improved our understanding of the capacity of stem cell-derived grafts to integrate within the host CNS. These studies have shown that grafted neurons, generated from either embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), are capable of extensive axonal growth over long distances, particularly via host white matter tracts ([@bib22], [@bib31], [@bib48]). However, it has thus far not been possible to characterize the specificity of these outgrowth patterns on the basis of neuronal phenotype.

Here we report that not only are grafted neurons generated from stem cells capable of long-distance innervation of host nuclei, but also that they have the capacity to do so with neuronal subtype specificity. Using a human ESC reporter line in which EGFP expression is driven by the endogenous *PITX3* promoter (*PITX3-*EGFP) allowed us to selectively identify DA-specific patterns of growth and connectivity. The results reveal the extent and specificity of dopaminergic innervation from ventral midbrain grafts generated from human PSCs. The DA neurons innervate developmentally appropriate A9 and A10 target structures with remarkable specificity, but represent only a minority of total graft outgrowth, which is largely non-dopaminergic and extends widely throughout the host brain.

Results {#sec2}
=======

Ventral Midbrain Differentiation of a Human PITX3-EGFP ESC Line {#sec2.1}
---------------------------------------------------------------

Here we used a reporter line with monoallelic insertion of EGFP into exon 1 of the *PITX3* gene so that both EGFP and PITX3 were driven by *PITX3* regulatory elements ([Figure 1](#fig1){ref-type="fig"}A). To generate ventral midbrain progenitors, we used the now widely favored approach ([@bib13], [@bib29], [@bib31], [@bib36]) that employs early signaling to instruct regional identity in parallel with neural induction ([Figure 1](#fig1){ref-type="fig"}B). As we have recently reported in detail under fully defined, xeno-free conditions ([@bib36]), this results in rapid and efficient neural (NESTIN^+^) specification of ventral midbrain (FOXA2^+^/OTX2^+^) progenitors as shown after 11 days *in vitro* (DIV) and acquisition of midbrain DA identity evident at the time of transplantation (19 DIV; [Figure 1](#fig1){ref-type="fig"}C).Figure 1A Human PITX3-eGFP ES Reporter Line for Identification of Midbrain DA Neurons(A) Monoallelic insertion of EGFP into exon 1 of the *PITX3* gene in the H9 human embryonic stem cell line to act as a reporter for PITX3 protein expression.(B) Schematic illustration of the differentiation procedure for specification of neural progenitors with ventral midbrain identity under defined, xeno-free conditions.(C) Differentiating cells show robust expression of markers consistent with neural (NESTIN^+^) and ventral midbrain/forebrain (FOXA2^+^/OTX2^+^) identity by 11 DIV and begin to show expression of PITX3-driven EGFP and TH at the time of transplantation (19 DIV). Scale bar, 50 μm.CHIR, CHIR99021; DIV, days *in vitro*; ECM, extracellular matrix; LDN, LDN193189; PM, purmorphamine; SB, SB431542; SHH, sonic hedgehog; TH, tyrosine hydroxylase.

Function and Composition of Human PITX3-EGFP Grafts {#sec2.2}
---------------------------------------------------

The experimental design is illustrated in [Figure 2](#fig2){ref-type="fig"}A, showing the timeline of rotational testing and the small subsets of animals taken for histology over the course of 7 months. The first group for histology at 4 weeks was to confirm successful engraftment, and single animals were taken at 10 and 18 weeks as a result of unrelated skin and respiratory complications. Rotational response to [d]{.smallcaps}-amphetamine showed that the grafts significantly reversed asymmetry previously induced by unilateral removal of the host midbrain DA neurons ([Figure 2](#fig2){ref-type="fig"}B). This was evident by 16 weeks and sustained up until the experimental endpoint at 28 weeks. Histological analysis showed a progressive, graft-specific, EGFP^+^ innervation of the host striatum by human DA neurons ([Figure 2](#fig2){ref-type="fig"}C). At 4 and 10 weeks, prior to significant change in rotational scores, few EGFP^+^ fibers were detected outside the immediate vicinity of the graft. At 18 weeks, dense areas of terminally ramified EGFP^+^ fiber networks could be observed, and this expanded to cover larger areas of the host striatum by 28 weeks. The grafts grew significantly in size from 0.8 ± 0.28 mm^3^ at 4 weeks (n = 4) to 7.04 ± 0.91 mm^3^ by 28 weeks (n = 10; Student\'s t test, p \< 0.01). The number of GFP^+^ DA neurons, however, did not expand over this time frame: 6,081 ± 659 at 4 weeks compared with 5,268 ± 654 at 28 weeks (Student\'s t test, p = 0.49).Figure 2PITX3-eGFP Grafts Progressively Innervate the Host and Correct Motor Function(A) Schematic illustrating experimental design and timeline. Tx, transplantation.(B) Animals with unilateral 6-OHDA lesions showed strong rotational asymmetry in response to 2.5 mg/kg (intraperitoneal) [d]{.smallcaps}-amphetamine that was significantly reduced in the group (mean ± SEM) that received transplants by 16 weeks and maintained at 28 weeks (Student\'s t test; n = 7 for control, n = 6 for grafted; ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.005).(C) Immunohistochemistry for EGFP in representative examples of grafted animals at 4, 10, 18, and 28 weeks showed the progressive innervation of host striatum over 6 months. Scale bar, 1 mm.

Immunohistological analysis showed EGFP^+^ to be a robust indicator of DA neuronal identity *in vivo* with the vast majority (86.5%) of EGFP^+^ cells also identified as tyrosine hydroxylase positive (TH^+^) ([Figure 3](#fig3){ref-type="fig"}A). Grafted DA neurons also expressed mature markers indicative of the capacity to store and release dopamine, including both the vesicular monoamine transporter (VMAT2) and the dopamine transporter (DAT; [Figure 3](#fig3){ref-type="fig"}B). The EGFP^+^ neurons were clearly heterogeneous in nature and could be distinguished based on features representative of both the major A9 and A10 classes of midbrain DA neurons. This included smaller diameter (∼15--20 μm), spherical neurons consistent with A10 morphology ([Figures 3](#fig3){ref-type="fig"}C and 3H) and also larger (∼20--50 μm), pyramidal neurons typical of A9 phenotype ([Figures 3](#fig3){ref-type="fig"}D and 3H). Labeling for GIRK2 and CALBINDIN also showed a mix of DA subtypes ([Figures 3](#fig3){ref-type="fig"}E--3H). Large, GIRK2^+^ DA neurons that did not express CALBINDIN were often found in clusters near the edge of the grafts, while CALBINDIN^+^ DA subtypes were found throughout the grafts. Cell counting showed that the fractional contribution of distinct EGFP^+^ DA phenotypes based on expression of GIRK2 or CALBINDIN was: 46.8% ± 8.1% GIRK2^+^/CALBINDIN^−^, 20.8% ± 1.1% GIRK2^+^/CALBINDIN^+^, and 5.0% ± 1.6% GIRK2^−^/CALBINDIN^+^ ([Figure 3](#fig3){ref-type="fig"}I). A remaining 27.4% ± 5.7% of EGFP^+^ cells did not express either GIRK2 or CALBINDIN.Figure 3Immunohistochemical Identification of DA Neuronal Subtypes in Grafts at 28 Weeks(A) The vast majority of EGFP^+^ cells were TH^+^ with typical midbrain dopamine neuron morphology.(B--G) Most EGFP^+^ DA neurons also expressed VMAT and DAT with a punctate pattern typical for these proteins (closed arrowheads). Cytoplasmic distribution of EGFP showed a mix of neuronal morphologies including smaller spherical neurons typical for A10 identity (C), as well as large, angular cell soma typical for A9 neurons (D). The GFP^+^ neurons were also mixed based on GIRK2 and CALBINDIN expression and included EGFP^+^/GIRK2^+^/CALBINDIN^−^ (E--G; arrows, particularly at the periphery of the grafts), EGFP^+^/GIRK2^+^/CALBINDIN^+^ (E--G; open arrowheads), and a smaller contribution of EGFP^+^/GIRK2^−^/CALBINDIN^+^ neurons (E--G; closed arrowheads).(H) Comparison of the mean diameter (horizontal lines) of EGFP^+^ cells in the periphery of the graft (n = 100; sampled across 3 grafts) showed these cells were significantly larger than those located more centrally (n = 100; sampled across 3 grafts, Student\'s t test: ^∗∗∗∗^p \< 0.001).(I) Fractional contribution of GIRK2/CALBINDIN-expressing cell subtypes as a proportion of EGFP^+^ cells (mean ± SEM; n = 5 grafts). CALB, CALBINDIN.Scale bars, 100 μm (A, E--G) and 50 μm (B--D).

Human Stem Cell-Derived DA Neurons Specifically Innervate Appropriate Host Targets {#sec2.3}
----------------------------------------------------------------------------------

Dark-field imaging of chromogen-labeled immunohistochemistry for EGFP revealed a remarkably specific pattern of axonal outgrowth by the grafted DA neurons ([Figure 4](#fig4){ref-type="fig"}). Within the host striatum, EGFP^+^ fibers formed a dense fiber network covering large areas of the head of the striatum ([Figures 4](#fig4){ref-type="fig"}A and 4D). The EGFP^+^ fibers also extended long distances to innervate extra-striatal areas. A notable example included prominent growth along white matter tracts, coursing anterior to the graft through forceps minor to provide a robust innervation of the frontal cortex in a layer-specific pattern, and also the cingulate cortex directly overlying the graft ([Figures 4](#fig4){ref-type="fig"}A and 4B). A smaller innervation of the frontal cortex in the contralateral hemisphere via fibers projecting through the corpus callosum was also observed in some animals ([Figure 4](#fig4){ref-type="fig"}C). Other structures with distinct EGFP^+^ innervation included the perirhinal cortex ([Figure 4](#fig4){ref-type="fig"}E) and the islands of Calleja through the ventral pallidum and septum ([Figures 4](#fig4){ref-type="fig"}F and 4G).Figure 4PITX3-eGFP Reveals Specific Patterns of Graft-Derived DA Neuron Connectivity(A) Representative dark-field photomontages of chromogen-labeled GFP 28 weeks after grafting.(B--G) Boxed areas from (A) are shown at higher magnification to illustrate EGFP^+^ innervation of various host territories, including: frontal cortex ipsilateral (B) and contralateral (C) to the graft; the head of the striatum immediately rostral to the graft core (D); perirhinal cortex (E); and the islands of Calleja through the ventral palladium (F) and septum (G).Scale bars, 1 mm (A) and 500 μm (B--G).

Retrograde Tracing Reveals Neuronal Subtype Specificity for Axonal Outgrowth Patterns {#sec2.4}
-------------------------------------------------------------------------------------

To characterize the neuronal identity of graft-derived innervation of distinct host target areas, we microinjected Fluorogold (FG) into either the dorsolateral striatum ([Figures 5](#fig5){ref-type="fig"}A and 5B) or frontal cortex ([Figures 5](#fig5){ref-type="fig"}C and 5D) in separate groups of animals. The deposits of FG were verified as being discretely contained within the intended target sites and clearly separated from the graft itself ([Figures 5](#fig5){ref-type="fig"}A and 5C). Across 4 animals where FG was injected into the dorsolateral striatum, 79 FG^+^ cells were identified within the grafts and the majority of these (54; ∼68%) were EGFP^+^ DA neurons. These neurons appeared as predominately A9 in phenotype with 45 of 54 (∼83%) presenting as GIRK2^+^/CALBINDIN^−^ and a relatively large average diameter of 35.49 μm, while a smaller fraction of cells (9 of 54) presented as either GIRK2^−^/CALBINDIN^+^ or GIRK2^+^/CALBINDIN^+^ with a smaller average diameter of 20 μm ([Figures 5](#fig5){ref-type="fig"}B and 5E).Figure 5DA Neuronal-Subtype-Specific Innervation of Host TargetsSmall deposits of Fluorogold (FG) were injected into the dorsolateral striatum (A) or frontal cortex (C) 27 weeks after grafting. The deposits were verified as being located remotely to the graft core for each animal as shown in photomontages of fluorescent detection of EGFP (grayscale; note EGFP^+^ fiber network can be seen in the striatum) and FG (red) in representative coronal sections (A and B). Detection of FG (grayscale), EGFP (green), GIRK2 (red), and CALBINDIN (blue) in animals receiving FG in either the dorsolateral striatum (B) or frontal cortex (D) highlight representative examples of DA neuronal phenotypes projecting to these regions. A total of 79 FG^+^ grafted cells were detected in animals injected with FG in the dorsolateral striatum, of which 54 were EGFP^+^ DA neurons and a total of 105 were detected in animals injected in the frontal cortex, of which only 12 were EGFP^+^ DA neurons (E). For each FG^+^ cell the relative location on the axis between the center of the graft and the graft-host border is indicated as well as the soma size (maximum diameter) and the GIRK2/CALBINDIN expression profile. Dopamine neurons (EGFP^+^) retrogradely labeled (FG^+^) from the dorsolateral striatum are plotted on the left of the graph and EGFP^+^/FG^+^ neurons retrogradely labeled from frontal cortex are plotted on the right. A number of examples of GABA-containing neurons retrogradely labeled from cortex were also observed in the grafts (F).Scale bars, 1 mm (A and C); 50 μm (B, D, and F). The schematic in (A) is modified from an original created by Bengt Mattsson (Lund University, Sweden).

Retrograde uptake of FG from the frontal cortex identified a markedly different pattern of FG^+^ cells, with the vast majority across 3 animals having a non-DA identity (93/105; ∼89%). The 12 FG^+^/EGFP^+^ DA neurons were mixed in phenotype with respect to typical A9/A10 attributes. A total of 5 were GIRK2^+^/CALBINDIN^−^ and variable in size with an average diameter of 32.8 μm; while the remaining 7 expressed CALBINDIN---either alone or with GIRK2---and were notably smaller, with an average diameter of 21.86 μm ([Figures 5](#fig5){ref-type="fig"}D and 5E). Regardless of the FG injection site, larger cells with A9 features tended to reside toward the periphery of the graft, while the smaller, CALBINDIN-expressing fraction was distributed closer to the center ([Figure 5](#fig5){ref-type="fig"}E). A number of the non-DA neurons innervating the cortex co-expressed γ-aminobutyric acid (GABA) ([Figure 5](#fig5){ref-type="fig"}F), although the dense GABA immunoreactivity of the surrounding neuropil made it difficult to unambiguously quantify the proportion of FG^+^ cells.

Non-dopaminergic Neurons in Stem Cell-Derived Ventral Midbrain Grafts Show Extensive Patterns of Connectivity in the Host Brain {#sec2.5}
-------------------------------------------------------------------------------------------------------------------------------

Immunohistochemistry for EGFP and NeuN showed that the majority of differentiated neurons in the grafts were non-dopaminergic (EGFP^−^/NeuN^+^; [Figure 6](#fig6){ref-type="fig"}A). Many of these had a ventral identity, based on labeling for FOXA2, with examples also of NeuN^−^/FOXA2^+^ cells, particularly in central parts of the grafts, which may represent relatively immature ventralized progenitors. In terms of neurotransmitter phenotype, the grafts were highly immunoreactive for GABA ([Figure 6](#fig6){ref-type="fig"}B). The labeling pattern for GABA made it difficult to reliably identify GABA^+^ cell bodies, precluding quantification; however, some cases of clearly GABA^+^ neuronal profiles could be seen intermingled with grafted DA neurons ([Figure 6](#fig6){ref-type="fig"}C). We were not able to identify serotonin-, acetylcholine-, or noradrenaline-containing neurons.Figure 6Grafts are Heteregenous in Composition and Contain Predominately Non-DA Neuronal Subtypes(A) Immunohistochemistry for EGFP, NeuN, and FOXA2 at 28 weeks illustrates the relative contribution of DA neurons (EGFP^+^/NeuN^+^/FOXA2^+^) and non-DA neurons (NeuN^+^/GFP^−^) as well as ventralized (FOXA2^+^) cell types which included both neurons (NeuN^+^) and NeuN^−^, presumably immature, cell types (dashed lines approximate the graft-host border).(B and C) The graft was highly immunoreactive for GABA (red), where human NCAM defines the graft (blue) and EGFP (green) is included to show DA neurons (B). Individual GABA neurons are difficult to resolve but can be delineated in the enlarged boxed area (C).(D--L) Human-specific detection of NCAM in representative coronal sections (D) illustrates the overall extent of graft-derived fiber outgrowth, with prominent innervation of various host territories including, but not limited to: the frontal cortex contralateral (E) and ipsilateral (F) to the graft; lateral septal nuclei (G); perirhinal cortex (I); basolateral amygdala (J, contralateral hemisphere shown); and caudal aspects of the ventral hippocampus (L). Cells with glial morphology migrated extensively through host white matter tracts, particularly adjacent to the corpus callosum (H), and migrated long distances as far caudally as the midbrain (K).Scale bars, 100 μm (A and B), 50 μm (C), 1 mm (D), 200 μm (E; applies to E--L).

Detection of human-specific NCAM allowed for identification of the entirety of graft-derived fiber outgrowth ([Figure 6](#fig6){ref-type="fig"}D), which was substantially more extensive then the EGFP^+^ fiber patterns. The NCAM^+^ labeling was particularly prominent in frontal cortical areas ([Figures 6](#fig6){ref-type="fig"}E and 6F) and, again, notably more extensive than the EGFP^+^ fiber innervation. NCAM^+^ fibers extended widely throughout the rostrocaudal axis of both hemispheres, predominately coursing along host white matter tracts, to innervate many structures not targeted by EGFP^+^ DA innervation. This included discrete areas of concentrated fiber innervation indicative of target-directed growth, including the lateral septal nuclei ([Figures 6](#fig6){ref-type="fig"}D and 6G), perirhinal and entorhinal cortex ([Figures 6](#fig6){ref-type="fig"}D and 6I), basolateral amygdala ([Figures 6](#fig6){ref-type="fig"}D and 6J), periaqueductal gray, and caudal aspects of the ventral hippocampus ([Figures 6](#fig6){ref-type="fig"}D and 6L). Another notable feature was the presence of NCAM glia, which migrated extensively throughout the corpus callosum and adjacent cortical parenchyma and along the internal capsule as far caudally as the entopeduncular nucleus and cerebral peduncles ([Figures 6](#fig6){ref-type="fig"}D, 6H, and 6K).

An overlay of camera lucida-style reconstructions of immunohistochemistry for NCAM and EGFP illustrates the topographical distribution and relative density of dopaminergic and total (largely non-dopaminergic) patterns of graft-derived fiber outgrowth in the host brain ([Figure 7](#fig7){ref-type="fig"}A). Photomicrographs of the corresponding sections showed that the majority of TH^+^ fibers in the striatum were graft-derived EGFP^+^ origin, while in the cortex the EGFP^+^/TH^+^ fibers were clearly intermingled with a residual host derived EGFP^−^/TH^+^ fiber network ([Figure 7](#fig7){ref-type="fig"}B). Comparison of EGFP^+^ and NCAM^+^ fiber densities in specific host nuclei illustrated the relative contribution of DA and non-DA innervation of these areas ([Figure 7](#fig7){ref-type="fig"}C). There was no significant difference in EGFP^+^ and NCAM^+^ density in the dorsolateral striatum, indicating a largely dopaminergic innervation, while all other areas showed significantly greater NCAM^+^ density and, thus, substantial contribution from non-DA neuronal subtypes.Figure 7The Non-DA Component in ES-Derived Grafts Provides Extensive Innervation of the HostSchematic reconstruction of immunohistochemistry for NCAM and EGFP illustrates the extent and pattern of DA-specific innervation of the host (EGFP^+^/NCAM^+^, green) relative to the total non-DA innervation (EGFP^−^/NCAM^+^, red) in a representative example 28 weeks after grafting (A). Photomicrographs from the striatum and cortex show dense fiber EGFP^+^, TH^+^, and NCAM^+^ fiber networks and illustrate the relative contribution of NCAM^+^ fibers as substantially greater than the graft-derived DA innervation in both areas (B). Quantification of NCAM^+^ and EGFP^+^ fiber density (mean ± SEM; n = 5 grafts) in specific host nuclei illustrates the relative contribution of DA and non-DA innervation in each region (C; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.005; n.s., not significant).Scale bars, 1 mm (A) and 100 μm (B).

Discussion {#sec3}
==========

These results demonstrate the extent and specificity of host innervation from grafted DA neurons generated from human ESCs using contemporary differentiation and transplantation procedures. Under these conditions, *PITX3*-driven EGFP expression was highly specific for bona fide midbrain DA identity and thus allowed for precise characterization of DA-specific patterns of connectivity. The findings are similar to those from studies using fetal donor tissue from TH-GFP or *Pitx3*-GFP reporter mice ([@bib21], [@bib49]), showing that the grafts contain a mix of the major A9 and A10 DA neuronal subtypes and retain an intrinsic capacity to innervate multiple, developmentally appropriate host structures on a neuronal-subtype-specific basis. There were differences, however, that likely reflect species-specific aspects of midbrain cytoarchitecture and projection patterns.

The relative contribution of cell subtypes on the basis of GIRK2/CALBINDIN expression showed the predominant phenotype as GIRK2^+^/CALBINDIN^−^ (∼47%) and only a minority as GIRK2^−^/CALBINDIN^+^ (∼5%). This differs from grafts of fetal mouse midbrain, where there is a more marked distinction between GIRK2^+^ and CALBINDIN^+^ DA subtypes ([@bib21], [@bib49]) and may represent species-specific differences in GIRK2 expression---which is broader in the human midbrain, incorporating A10 areas ([@bib41])---but also the relatively greater ratio of A9 to A10 DA neurons in the primate brain compared to rodents (for review see [@bib4]). Innervation of extra-striatal territories was notably more extensive than has been reported in studies using donor tissue from reporter mice ([@bib49]), including a particularly robust innervation of frontal and cingulate cortices. Compared with rodents, the A9 DA neurons in the primate brain are known to provide a substantially greater innervation of the cortex ([@bib4], [@bib18], [@bib33]). In line with this, the retrograde tracing experiments showed that while innervation of the dorsolateral striatum was overwhelmingly provided by grafted DA neurons with A9 properties, the cortex, which is predominately innervated by A10 subtypes in rodent grafting studies ([@bib49]), received innervation from both A9 and A10 subtypes. Thus overall, grafted DA neurons generated from human ESCs retain an intrinsic capacity for neuronal-subtype-specific patterns of target-directed outgrowth. These results also highlight the requirement for differentiation procedures resulting in appropriately patterned A9 neurons for establishment of terminal networks in territories relevant for restoration of motor function, including the dorsolateral striatum.

Both the time course for impact on motor function and the development of a graft-derived DA terminal network in the striatum were notably protracted. The first significant reduction in amphetamine-induced rotational asymmetry was apparent from 16 weeks and was complemented by the progressive development in density of striatal innervation between 10 and 28 weeks. This is consistent with other recent grafting studies using human embryonic stem ([@bib30], [@bib31], [@bib36]) or induced pluripotent stem ([@bib16], [@bib28]) donor cells, where functional impact required 3--5 months, and also observations in PD patients receiving fetal tissue grafts, in whom clinical improvement occurs gradually between 6 and 24 months ([@bib34]). It supports the view that, irrespective of the fetal or stem cell origin of the donor material, therapeutic benefit requires that grafted midbrain DA neurons establish a functional terminal network and is unlikely to be related to indirect mechanisms, such as neuroprotection or host neuroplasticity, as has been suggested in recent studies using parthenogenetic stem cells ([@bib20]). Such conclusions are also supported by recent studies using light-activated opsins ([@bib46]) or synthetic ligand-receptor systems ([@bib10]) to illustrate the relationship between correction of motor function and functional integration of implanted DA neurons.

Use of a *PITX3-*EGFP reporter line provided the unique opportunity to assess the relative contribution of host innervation from midbrain DA neurons compared with the total extent of graft-derived host connectivity. The results showed that the overwhelming majority of graft-derived outgrowth was non-dopaminergic, even in DA-specific target areas including the striatum and cortex. Non-dopaminergic axonal growth extended predominately via host white matter tracts to provide extensive innervation of remote nuclei throughout both hemispheres. In some areas, including amygdaloid nuclei, the pattern of connectivity appeared highly targeted, suggesting innervation by phenotypically specified neuronal subtypes. The overall pattern of fiber outgrowth was similar to those reported in fetal ventral mesencephalic xenografting studies ([@bib25], [@bib52]), which also include a predominately non-DA component. To some degree this may reflect developmentally appropriate outgrowth of non-DA ventral midbrain neuronal subtypes, for example GABAergic projection neurons of the substantia nigra pars reticulata, ventral tegmental area, and mammillary region that are known to project extensively to thalamus and cortex ([@bib3], [@bib12], [@bib44]). We identified GABA-containing cells in the stem cell-derived grafts, including those that innervated the host cortex; however, both here and in other recent studies ([@bib16], [@bib22], [@bib24], [@bib30], [@bib31], [@bib42]), the majority of grafted neurons were not readily identified based on neurochemical features. This may indicate that many of the immature neural progenitors in the donor cell preparations are insufficiently specified to acquire a terminally differentiated phenotype after transplantation. In this case it is possible that the axonal growth trajectories will be through permissive growth corridors determined by the host environment, rather than intrinsically specified patterns of target-directed connectivity. Consistent with such an explanation, very similar growth patterns characterized by extensive elongation along host white matter tracts has been observed also after transplantation of other donor cell identities, including cortical cell types ([@bib14], [@bib37], [@bib59]). The functional consequences of non-DA connectivity remain largely unknown. While this is an area for ongoing work, it is worth noting that the similarly large contribution of non-DA neuronal outgrowth from fetal grafts has not been identified as problematic or offsetting the overall therapeutic impact provided by the DA neuronal replacement. One notable exception is the inclusion of serotonin neurons, which have been reported as a risk for graft-induced dyskinesia ([@bib7], [@bib8], [@bib39]).

The average yield of DA neurons in the grafts at 28 weeks was 5,268 ± 654 per 100,000 cells implanted. This figure is consistent across a number of recent grafting studies using similar experimental designs, including reports of ∼3,716 ([@bib30]), ∼6,000 ([@bib31]), and ∼8,338 ([@bib29]) for ESCs and ∼3,436 ([@bib16]) and ∼8,849 ([@bib42]) for iPSCs. Thus the final yield of DA neurons using currently available differentiation and transplantation techniques is in the order of 3.4%--8.8% of cells implanted. This fractional contribution may become considerably smaller with continued growth of the non-DA component over time. Here we observed that the number of DA neurons did not expand between 4 (6,081 ± 659) and 28 weeks (5,268 ± 654), while there was a significant increase in graft volume from 0.8 ± 0.28 mm^3^ to 7.04 ± 0.91 mm^3^ over the same time frame. We have previously reported that neural grafts derived from human PSCs exhibit ongoing cell proliferation *in vivo* as the basis for expansion of the graft volume ([@bib14], [@bib37]). Human fetal grafts are also known to expand *in vivo* ([@bib32]) and, thus, expansion of stem cell-derived grafts may represent normal developmental growth properties of human neural tissue. On current evidence, however, one cannot unambiguously exclude the possibility of slow but potentially pathological growth over clinically relevant post-transplantation time frames. This is an area that warrants further attention and various strategies are actively being pursued to safeguard against this risk, including the use of cell-sorting techniques to remove unwanted cell types ([@bib16], [@bib19], [@bib42]) or ligand-activated suicide genes to eliminate proliferating cells *in vivo* ([@bib27], [@bib54]). A recent study by [@bib30] highlights that there is also scope for ongoing refinement of differentiation procedures to optimize graft composition, with increased efficiency in specification of midbrain DA identity *in vitro* resulting in a significant increase in DA neuron density in the resulting grafts.

In summary, we report here that midbrain DA neurons generated from human ESCs establish highly specific patterns of growth *in vivo*, including innervation of developmentally appropriate targets on a DA neuronal-subtype-specific basis. The delayed onset of functional recovery and protracted course of striatal innervation by midbrain DA neurons with predominately A9 features reinforces the notion that therapeutic benefit from stem cell-based treatments for PD requires functional integration of correctly specified DA neuronal subtypes. Furthermore, the relatively small contribution of DA neurons to the overall pattern of neuronal integration highlights the scope for further refinement of current differentiation and transplantation protocols. This should include efforts to limit the inclusion of unwanted or uncharacterized cell types. The inability to standardize and characterize fetal tissue preparations prior to transplantation has been recognized as one of the key factors underlying highly variable clinical outcomes to date ([@bib2], [@bib51]). It is therefore imperative that the same issues are avoided as enthusiasm builds for advancement of human PSCs toward clinical trials in patients with PD. Recent advances in differentiation ([@bib30]) and cell sorting ([@bib16], [@bib19], [@bib42]) procedures give cause for optimism.

Experimental Procedures {#sec4}
=======================

Animals and Ethics {#sec4.1}
------------------

All procedures were conducted in accordance with the Australian National Health and Medical Research Council\'s published Code of Practice for the Use of Animals in Research, and experiments were approved by the Florey Institute of Neuroscience and Mental Health Animal Ethics Committee.

A total of 23 male athymic (CBH^rnu^) rats at 8--9 weeks of age (∼150 g) were used at the beginning of this study. The animals were group housed in individually ventilated cages with Alpha-dri paper bedding material (Abel Scientific, Perth) to reduce skin and eye irritation and housed on a 12:12-hr light/dark cycle with *ad libitum* access to food and water.

Human Pluripotent Stem Cell Culture {#sec4.2}
-----------------------------------

The human embryonic stem cell *PITX3*-EGFP reporter line was generated on an H9 background as originally described ([@bib55]) and expanded and differentiated under xeno-free conditions also as previously described in detail ([@bib36]). In brief, neural induction was achieved via dual SMAD inhibition using LDN193189 (200 nM, days 0--11; Stemgent) and SB431542 (10 μM, days 0--5; R&D Systems). Ventral midbrain patterning was achieved by addition of sonic hedgehog (C25II, 100 ng/mL; R&D Systems), purmorphamine (2 μM, days 1--7; Stemgent), and CHIR99021 (3 μM, days 3--13; Miltenyi). At day 19, cultures rich in ventral midbrain progenitors were dissociated with Accutase (Innovative Cell Technologies) and prepared for transplantation as a cell suspension in day-19 culture medium supplemented with 0.05% DNase (Sigma).

Surgical Procedures and Rotational Behavior {#sec4.3}
-------------------------------------------

Anesthesia for all surgical procedures was induced and maintained by inhaled isoflurane (2%--5% in air). All 23 athymic rats received stereotaxic injection of 3.5 μL 6-hydroxydopamine (6-OHDA) (3.2 μg/μL free base) unilaterally into the medial forebrain bundle (3.4 mm caudal and 1.3 mm lateral to bregma and 6.8 mm below the dural surface) as previously described ([@bib53]). Three weeks later, all animals were tested for rotational asymmetry after administration of [d]{.smallcaps}-amphetamine sulfate (2.5 mg/kg, intraperitoneally) as described by [@bib53]. A cohort of 13 out of 23 of the animals satisfied our criteria of \>7 full turns/min for designation of stable rotational asymmetry. For longitudinal assessment of rotational behavior, these animals were divided into a control group (n = 7) and a transplantation group (n = 6). The remaining 10 animals received grafts of ventral midbrain progenitors for additional histological analysis only.

One week after pre-graft rotational assessment (4 weeks after 6-OHDA) a total of 16 6-OHDA-lesioned animals received single 1-μL injections of pre-differentiated human *PITX3*-EGFP donor cells (1 × 10^5^ cells/μL) into the rostral head of the striatum as previously described in detail ([@bib53]). Assessment of amphetamine-induced rotational behavior was performed at 8, 16, and 28 weeks after transplantation.

For retrograde labeling of grafted neurons, a Neuros syringe (Hamilton) was used to microinject 0.1 μL of a 2% solution of Fluorogold (Fluorochrome) into either the dorsolateral striatum (n = 5; 1.2 mm rostral, 3.4 mm lateral to bregma; 3.6 mm below dura) or frontal cortex (n = 5; 2.7 mm rostral, 1 mm lateral to bregma; 2 mm below dura). Tracing was performed 1 week prior to the experimental endpoint at 28 weeks.

Immunohistochemistry {#sec4.4}
--------------------

For histological assessment, animals were perfusion fixed (4% paraformaldehyde) and the brains were cut on the coronal plane using a freezing microtome as previously described ([@bib49]). Four animals were taken for histological assessment 4 weeks after transplantation to confirm successful engraftment, with the remainder taken at 28 weeks (n = 10). Additionally, 2 animals were perfused at 10 and 18 weeks due to spontaneous development of skin irritations that are not uncommon with long-term housing of athymic rats. This facilitated useful, albeit qualitative information on the progressive development of DA innervation of the host striatum over time ([Figure 1](#fig1){ref-type="fig"}B).

Immunohistochemical procedures on free-floating tissue sections were as described previously in detail ([@bib49]). Primary antibodies and dilutions included: 5HT (mouse, 1:10,000, Immunostar: 20080); CALBINDIN (mouse, 1:1,000, Swant Biotech: CB300); ChAT (rabbit, 1:1,000, Millipore: AB143); DAT (rat, 1:1,000, Millipore: MAB369) FoxA2 (rabbit, 1:300, SCBT: sc-6554); GFP (chicken, 1:5,000, Abcam: AB13970); GABA (rabbit, 1:5,000, Sigma: A2052); GIRK2 (rabbit, 1:500, Alomone Labs: APC-006); NeuN (mouse, 1:200, Millipore: MAB377); dopamine-β-hydroxylase (mouse, 1:10,000, Millipore: MAB308); NCAM (mouse, 1:500, clone eric-1, SCBT: sc-106); TH (rabbit or sheep, 1:800, PelFreeze: P40101-0 or P60101-0); VMAT2 (rabbit, 1:1,000, Millipore: AB1598P). The bound primary antibody was detected either through enzymatic conjugation of the diaminobenzidine chromagen or fluorescent secondary antibodies (Jackson Immunoresearch).

Imaging and Graft Reconstructions {#sec4.5}
---------------------------------

A Leica microscope (DM6000) with a motorized x-y stage was used to capture photomontages of whole coronal sections with chromogen-labeled EGFP or NCAM. Images were acquired either in bright field or dark field to visualize graft-derived fiber outgrowth. Photomicrographs of immunofluorescence were acquired using a Zeiss (Z780) microscope.

For analysis of cells labeled by retrograde FG uptake, cell size was recorded as the longest linear diameter for each FG^+^ cell. The relative position of each FG^+^ cell within the graft was calculated by determining the radial size of the graft on the dorsoventral and mediolateral axes and determining the distance from the edge of the graft along the nearest axis. To normalize for different graft sizes, the results are reported as a fractional distance along the axis where the graft periphery and center are assigned as 0 and 1, respectively.

High-resolution photomontages of whole coronal sections immunolabeled for EGFP and NCAM were used to schematically illustrate the extent and pattern of DA (EGFP) and total (NCAM) outgrowth. The "select\>color-range" tool (Photoshop 13.0.6, Adobe) was initially used to define and select the bulk of the EGFP or NCAM signal. Conservative threshold levels were used to avoid selection of background signal. Each section was subsequently annotated manually by carefully tracing over the remaining fibers using a tablet-stylus interface (Intuos Pro, Wacom) and Canvas Draw software (3.0.5, ACD Systems).

Quantification and Statistics {#sec4.6}
-----------------------------

Rotational response to amphetamine was quantified using an automated system as described by [@bib6] and group difference in mean assessed separately at each time point by Student\'s unpaired t test (control, n = 7; graft, n = 8 at each time point).

The mean number of EGFP cells at 4 weeks (n = 4) and 28 weeks (n = 10) was determined by counting all cells in 6 series for each animal. Double-counting error was corrected by the method of Abercrombie according to section thickness and average cell diameter ([@bib1]). The size of 200 EGFP^+^ cells was measured as the largest linear diameter and was used to compare cell size in the periphery of the graft---defined as within 300 μm of the host-graft interface---with those located in the center. Graft volumes were calculated in the same animals by extrapolation of the cumulative area measured in 6 series using Cavalieri\'s principle ([@bib9]). Difference in mean volume between the 4-week (n = 4) and 28-week (n = 10) time point was assessed using Student\'s t test.

The overlap between TH and EGFP was determined through careful inspection of 267 EGFP^+^ cells in confocal datasets including separate channel information on the x, y, and z axes. Similarly, the GIRK2^+^/CALBINDIN^+^ profile of grafted DA neurons was assessed through careful inspection of all EGFP^+^ cells in grafts (n = 5) in single sections captured via confocal microscopy.

The relative density of graft-derived DA (EGFP^+^/NCAM^+^) or non-DA (EGFP^−^/NCAM^+^) fiber networks was assessed in specific host nuclei by measurement of EGFP^+^ (n = 7) and NCAM^+^ (n = 3) immunolabeled fibers as the fractional pixel contribution to single photomicrographs acquired using a 40× objective. Difference in the mean density at each location was assessed using Student\'s t test.
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